Novocure (NASDAQ: NVCR) announced good news earlier this month from a late-stage study evaluating its Tumor-Treating Fields (TTFields) therapy in treating non-small cell lung cancer (NSCLC). Its shares skyrocketed.

But just a few days later, the company provided a sneak peek at its 2022 fourth-quarter and full-year results. The numbers weren't all that great. In addition, a top analyst raised questions about how positive Novocure's NSCLC results actually were. The stock quickly gave up some of its earlier gains.

The battle between the Novocure bulls and bears will likely continue to play out throughout this year. Will Novocure stock sink or soar in 2023?

Continue reading

Source Fool.com